What You Need to KnowBackgroundWe described the characteristics of liver function and its relation with severity and prognosis in patients with SARS-CoV-2 and chronic hepatitis B virus (HBV) coinfection.FindingsPatients with SARS-CoV-2 and chronic HBV coinfection who developed liver injury were more likely to progress into severe illness and had a worse prognosis including higher mortality and incidence of complications such as acute-on-chronic liver failure, acute cardiac injury, and shock.Implications for patient careLiver function should be evaluated more frequently in patients with SARS-CoV-2 and chronic HBV coinfection, especially within 1 week after admission.

In December 2019, pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), now known as coronavirus disease 2019 (COVID-19), was first reported in Wuhan, China. It has subsequently spread throughout China and other countries. A total of 750,890 cases and 36,405 deaths had been reported all over the world by March 31, 2020.[@bib1] It has emerged as a major global health threat. According to recent reports, 2%--11% of COVID-19 patients had liver comorbidities, and 14%--35% of cases with abnormal levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) during disease progression have been reported.[@bib2], [@bib3], [@bib4], [@bib5] However, the exact cause of preexisting liver conditions had not been outlined in these studies.

Hepatitis B virus (HBV) infection correlated with the development of cirrhosis, liver failure, and hepatocellular carcinoma remains a major public health problem worldwide. The prevalence of hepatitis B surface antigen (HBsAg) was estimated to be 5%-6% in the general population, with about 70 million cases of chronic HBV infection in China.[@bib6] A recent report showed that SARS-CoV-2 might mainly act on lymphocytes, especially T lymphocytes.[@bib7] In the course of HBV infection, HBV-specific T lymphocytes play an important role in viral clearance and liver inflammation. Functional and quantitative defects in the HBV-specific T-cell response are associated with viral persistence.[@bib8] Whether the existence of HBV would affect the SARS-CoV-2 infection remains unknown. Would SARS-CoV-2 infection in patients with chronic HBV infection lead to deterioration of liver function? The characteristics of liver function in patients with SARS-CoV-2 and chronic HBV coinfection have not been reported yet.

In this study, we aimed to describe the characteristics of liver function and its relation with severity and prognosis in patients with SARS-CoV-2 and chronic HBV coinfection to provide evidence for the clinical treatment of these specific patients and contribute to improving their prognosis.

Methods {#sec1}
=======

Study Design and Participants {#sec1.1}
-----------------------------

This is a single-center, retrospective study of 105 patients with SARS-CoV-2 and chronic HBV coinfection hospitalized at Tongji Hospital. Tongji Hospital is one of the major comprehensive medical treatment centers assigned for the treatment for severe COVID-19 patients by the government. We recruited inpatients from February 1 to February 29, 2020 who had been diagnosed as having COVID-19 and chronic HBV infection according to World Health Organization interim guidance and American Association for the Study of Liver Diseases guidelines.[@bib9] ^,^ [@bib10] All patients had a history of chronic HBV infection and tested positive for HBsAg at admission. Laboratory confirmation of COVID-19 was performed by the local health authority as previously described.[@bib7] The ethics committee of Tongji Hospital approved this study (TJ-IRB20200225).

Data Collection {#sec1.2}
---------------

Data extraction was performed by a trained team of physicians using a standardized form to collect data on demographic characteristics, duration from illness onset to hospitalization, underlying chronic medical conditions, symptoms from onset to admission, continuous laboratory test results, treatments, complications, and outcomes from electronic medical records. The information on anti-HBV treatment was collected by medical history. HBV serologic markers were tested by using commercially available microparticle enzyme immunoassay kits (Axsym; Abbott Laboratories, Abbott Park, IL). HBsAg \>0.05 IU/mL was considered HBsAg-positive. Hepatitis B virus e antigen (HBeAg) \<1 IU/mL and ≥1 IU/mL meant HBeAg-negative and HBeAg-positive, respectively.

Severe illness of COVID-19 was defined as one of the following: respiratory rate \>30 breaths/min, severe respiratory distress, or oxygen saturation ≤93% on room air.[@bib9] Liver test abnormalities were defined by the abnormal of the following indices in serum: ALT \>41 U/L, AST \>40 U/L, gamma-glutamyl transferase (γ-GT) \>71 U/L, alkaline phosphatase (ALP) \>130 U/L, or total bilirubin (TBIL) \>26 μmol/L. Liver injury was defined as ALT and/or AST over 3× upper limits of normal (ULN) and/or TBIL over 2× ULN.[@bib11] Acute-on-chronic liver failure (ACLF) was defined as TBIL ≥5 mg/dL (85 μmol/L) and coagulopathy (international normalized ratio \[INR\]  ≥1.5 or prothrombin activity \<40%) complicated within 4 weeks by clinical ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease/cirrhosis, according to the Asian Pacific Association for the Study of the Liver.[@bib12] Acute respiratory distress syndrome was defined according to the Berlin definition.[@bib13] Acute kidney injury was identified according to the Kidney Disease: Improving Global Outcomes definition.[@bib14] Acute cardiac injury was defined as the serum levels of hypersensitive troponin I were above 34.2 pg/mL or new abnormalities were shown in electrocardiography and echocardiography.[@bib15]

Statistical Analysis {#sec1.3}
--------------------

Values are presented as number (%) for categorical variables and median (interquartile range \[IQR\]) for continuous variables, respectively. The differences of categorical variables between patients with and without liver injury were compared by χ^2^ test or Fisher exact test when appropriate, and continuous variables were compared by using Wilcoxon tests. A *P* value less than .05 was considered statistically significant. All analyses were performed with SAS 9.4 (SAS Institute, Cary, NC).

Results {#sec2}
=======

Of 105 patients with SARS-CoV-2 and chronic HBV coinfection, 14 (13.33%) had liver injury, and 4 (3.81%) developed ACLF during the hospitalization.

Clinical Characteristics {#sec2.1}
------------------------

The median age of these patients was 62 years (IQR, 51--70), and 55 patients (52.38%) were male. The most common symptoms from onset to admission were fever (85, 80.95%) and cough (81, 77.14%), followed by dyspnea (51, 48.57%) and fatigue (36, 34.29%). Forty-two patients (40%) had comorbidities, with hypertension (27, 25.71%) being the most common comorbidity. Five patients (4.76%) had malignancy, and 1 patient (0.95%) had hepatocellular carcinoma. Two patients (1.90%) had cirrhosis. No patient had human immunodeficiency virus coinfection, and only 1 patient (0.95%) had hepatitis C virus coinfection. Thirteen patients (12.38%) were taking nucleotide/nucleoside analogues therapy anti-HBV, including 9 (8.57%) with entecavir, 3 (2.86%) with tenofovir, and 1 (0.95%) with lamivudine and adefovir. A majority of patients (102, 97.14%) tested negative for HBeAg. Fifty-six patients (53.33%) were severe COVID-19 cases. The median interval from onset to hospitalization was 10 days (IQR, 7--18).

Liver injury was more common in male patients than in female patients (92.86% vs 46.15%, *P* = .001). The incidence of fever was higher in patients with liver injury (*P* = .011). Values of HBsAg and HBV core antibody were not significantly different in the 2 groups (both *P* \> .05). The proportion of severe COVID-19 was higher in patients with liver injury (*P* = .042) ([Table 1](#tbl1){ref-type="table"} ).Table 1Basic Characteristics of Patients With SARS-CoV-2 and Chronic HBV CoinfectionVariablesAll patients (N = 105)Liver injury (N = 14)Non-liver injury (N = 91)*P* valueAge (*y*)62 (51--70)54 (42--67)63 (51--70).109Sex Male55 (52.38)13 (92.86)42 (46.15)**.001** Female50 (47.62)1 (7.14)49 (53.85)Smoking5 (4.76)0 (0.00)5 (5.49).226Chronic medical illness Any42 (40.00)7 (50.00)35 (38.46).412 Diabetes10 (9.52)1 (7.14)9 (9.89).736 Hypertension27 (25.71)4 (28.57)23 (25.27).795 Coronary heart disease7 (6.67)1 (7.14)6 (6.59).939 Chronic obstructive pulmonary disease3 (2.86)0 (0.00)3 (3.30).350 Malignancy5 (4.76)2 (14.29)3 (3.30).126 Cirrhosis2 (1.90)0 (0.00)2 (2.20).447HBsAg, *IU/mL*97.42 (8.22--250)33.14 (10.60--250)99.88 (7.94--250).949HBeAg, *IU/mL* \<1102 (97.14)14 (100.00)88 (96.70)1.00 ≥13 (2.86)0 (0.00)3 (3.30)HBcAb, *IU/mL*9.94 (9.30--10.39)9.98 (8.94--10.29)9.94 (9.32--10.40).75Nucleotide/nucleoside analogues therapy13 (12.38)1 (7.14)12 (13.19).523Symptoms from onset to admission Fever85 (80.95)14 (100.00)71 (78.02)**.011** Cough81 (77.14)11 (78.57)70 (76.92).891 Hemoptysis2 (1.90)0 (0.00)2 (2.20).447 Dyspnea51 (48.57)9 (64.29)42 (46.15).204 Fatigue36 (34.29)3 (21.43)33 (36.26).260 Vomiting4 (3.81)1 (7.14)3 (3.30).523 Diarrhea19 (18.10)4 (28.57)15 (16.48).299Interval from onset to hospitalization, *days*10 (7--18)9.5 (8--13)12 (7--19).277Severity of COVID-19 Non-severe49 (46.67)3 (21.43)46 (50.55)**.042** Severe56 (53.33)11 (78.57)45 (49.45)[^2][^3]

Liver Function at Admission and During Hospitalization {#sec2.2}
------------------------------------------------------

Elevated levels of liver tests were seen in several patients at admission, with elevated ALT, AST, TBIL, ALP, and γ-GT in 22 (20.95%), 29 (27.62%), 7 (6.67%), 1 (0.95%), and 7 (6.67%) patients, respectively. Among the patients with liver test abnormalities, most were mildly elevated within 1--2× ULN at admission. Fourteen patients (13.33%) presented with reduced prothrombin activity (65; IQR, 55--70) and prolonged INR (1.33; IQR, 1.28--1.52) at admission.

By comparing the peak value of liver tests during hospitalization with the value at admission, the levels of ALT, AST, TBIL, ALP, and γ-GT increased substantially during hospitalization (all *P* \< .05). The proportion of ALT abnormalities and ALT over 3× ULN was increased after admission (*P* = .021) ([Table 2](#tbl2){ref-type="table"} ).Table 2Liver Test Results of Patients With SARS-CoV-2 and Chronic HBV Coinfection at Admission and During HospitalizationVariableAt admissionPeak value*P* valueALT, *U/L*, median (IQR)23 (15--33)32 (23--50)**\<.001** Normal83 (79.05)67 (63.81)**.021** 1--2× ULN, n (*%*)17 (16.19)29 (27.62) 2--3× ULN, n (*%*)3 (2.86)1 (0.95) \>3× ULN, n (*%*)2 (1.90)8 (7.62)AST, *U/L*, median (IQR)28 (19--43)35 (24--53)**.002** Normal76 (72.38)62 (59.05).202 1--2× ULN, n (*%*)22 (20.95)35 (33.33) 2--3× ULN, n (*%*)5 (4.76)5 (4.76) \>3× ULN, n (*%*)2 (1.90)3 (2.86)TBIL, *μmol/L*, median (IQR)8.3 (6.6--12.8)11.5 (7.9--16.2)**.031** Normal98 (93.33)92 (87.62).272 1--2× ULN, n (*%*)6 (5.71)9 (8.57) 2 --3× ULN, n (*%*)0 (0.00)2 (1.90) \>3× ULN, n (*%*)1 (0.95)2 (1.90)ALP, *U/L*, median (IQR)62 (50--76)72 (59--87)**\<.001** Normal104 (99.05)100 (95.24).084 1--2× ULN, n (*%*)1 (0.95)5 (4.76)γ-GT, *U/L*, median (IQR)24 (16--36)35 (23--55)**\<.001** Normal98 (93.33)91 (86.67).193 1--2× ULN, n (*%*)5 (4.76)10 (9.52) 2--3× ULN, n (*%*)2 (1.90)2 (1.90) \>3× ULN, n (*%*)0 (0.00)2 (1.90)PTA, *%*, median (IQR)89 (84--99)86 (76--93).998 75--12591 (86.67)85 (80.95).409 40--7413 (12.38)17 (16.19) \<401 (0.95)3 (2.86)INR, median (IQR)1.07 (1.00--1.11)1.10 (1.04--1.18)1.000 0.8--1.291 (86.67)83 (79.05).261 1.2--1.510 (9.52)18 (17.14) \>1.54 (3.81)4 (3.81)[^4][^5]

Treatments During Hospitalization and Clinical Outcomes {#sec2.3}
-------------------------------------------------------

Antiviral therapy, including arbidol, lopinavir/ritonavir, interferon, and ribavirin, were given to nearly all patients (102, 97.14%). More patients received interferon atomization therapy in liver injury group (*P* = .018). Methylprednisolone and oxygen therapy were given to more patients with liver injury (*P* = .016 and .031, respectively). ACLF, acute cardiac injury, and shock happened more frequently in patients with liver injury (all *P* \< .05). Up to March 10, 2020, 44 patients (41.90%) were still hospitalized; 55 patients (52.38%) had been discharged, and 7 patients (6.67%) died. The mortality was significantly higher in individuals with liver injury (28.57% vs 3.30%, *P* = .004) ([Table 3](#tbl3){ref-type="table"} ).Table 3Treatments During Hospitalization and Outcomes of Patients With SARS-CoV-2 and Chronic HBV CoinfectionAll patients (N = 105)Liver injury (N = 14)Non-liver injury (N = 91)*P* valueTreatments Antiviral102 (97.14)13 (92.86)89 (97.80).367 Arbidol82 (78.10)9 (64.29)73 (80.22).320 Lopinavir/ritonavir16 (15.24)3 (21.43)13 (14.29).770 Interferon9 (8.57)4 (28.57)5 (5.49)**.018** Ribavirin8 (7.62)1 (7.14)7 (7.69).942 Antibiotic62 (59.05)11 (78.57)51 (56.04).111 Methylprednisolone30 (28.57)8 (57.14)22 (24.18)**.016** Intravenous9 (8.57)4 (28.57)5 (5.49)**.021** Oral21 (20.00)4 (28.57)17 (18.68) Immunoglobulin23 (21.90)6 (42.86)17 (18.68).057 Oxygen therapy90 (85.71)14 (100.00)76 (83.52)**.031** Nasal cannula69 (65.71)8 (57.14)61 (67.03).474 High flow nasal cannula or NIV15 (14.29)4 (28.57)11 (12.09).132 IMV6 (5.71)2 (14.29)4 (4.40).193Complications ARDS47 (44.8)8 (57.14)39 (42.86).317 ACLF4 (3.81)4 (28.57)0 (0.00)**\<.001** Acute cardiac injury14 (13.33)5 (35.71)9 (9.89)**.019** Acute kidney injury4 (3.81)2 (14.29)2 (2.20).070 Shock3 (2.86)2 (14.29)1 (1.10)**.029**Duration of hospitalization, *days*22 (14--28)23.5 (9--28)21 (14--28).769Death7 (6.67)4 (28.57)3 (3.30)**.004**[^6][^7]

Course of Illness in Patients With Liver Injury {#sec2.4}
-----------------------------------------------

Fourteen patients (13.33%) developed liver injury during hospitalization. The interval from onset to hospitalization of patients with liver injury was 9.5 days (IQR, 8--13). Thirteen patients (92.86%) developed liver injury within a week of admission. Liver tests of most patients (10, 71.43%) recovered normality after 8 days (range, 6--21). However, the other 4 patients (28.57%) rapidly progressed to ACLF, and all of them died of multiple organ failure ([Figure 1](#fig1){ref-type="fig"} ).Figure 1Course of illness in patients with SARS-CoV-2 and chronic HBV coinfection who had liver injury. *Bars* represent course of illness from onset to liver tests recovery or death of each patient. ACLF, acute-on-chronic liver failure.

The peak values of ALT, AST, TBIL, ALP, and γ-GT in the 4 patients with ACLF were 101.75 ± 66.64 U/L, 113.50 ± 60.58 U/L, 119.7 ± 15.94 μmol/L, 115.25 ± 21.93 U/L, and 132.00 ± 80.56 U/L, respectively. All of them developed ascites. None of them suffered encephalopathy and underwent autopsy.

Discussion {#sec3}
==========

In the present study, we found that liver test abnormalities were relatively common in patients with SARS-CoV-2 and chronic HBV coinfection, and the values of ALT, AST, TBIL, ALP, and γ-GT increased substantially during hospitalization. A small portion of patients developed liver injury. Patients with liver injury were more likely to develop severe illness and had a worse prognosis including higher mortality and incidence of complications.

The present study reported evidence of liver injury in patients with SARS-CoV-2 and chronic HBV coinfection. Several patients had various abnormal liver tests. According to previous studies, the incidences of ALT and AST abnormalities were 14.34%--29.5% and 17.9%--35%, respectively,[@bib2] ^,^ [@bib4] ^,^ [@bib5] ^,^ [@bib16] which were similar to ours. Liver injury occurred in 21.5% of patients with COVID-19 during hospitalization as Cai et al[@bib17] reported, which was higher than that in our study (13.33%). Several reasons may explain this. First, the 2 studies used different criteria for liver injury. We defined ALT and/or AST over 3× ULN and/or TBIL over 2× ULN as liver injury according to the protocol for prevention, diagnosis, and treatment of liver injury in COVID-19,[@bib11] whereas liver injury was defined as ALT and/or AST over 3× ULN and ALP, γ-GT, and/or TBIL over 2× ULN in the study of Cai et al. Second, the interval from onset to admission of patients in the present study was 10 days, which may lead to the missed diagnosis of early liver injury for lack of data before admission. Furthermore, there is heterogeneity in the population characteristics included in the 2 studies.

Whether liver injury in COVID-19 is worth taking seriously remains controversial.[@bib18] ^,^ [@bib19] A recent study showed the presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia.[@bib17] In our study, patients with liver injury were more likely to develop severe illness and had a worse prognosis including higher mortality and incidence of complications such as ACLF, acute cardiac injury, and shock. Liver injury happened to most patients within 1 week, and they recovered normality after several days. However, 4 chronic HBV-infected patients deteriorated rapidly after SARS-CoV-2 coinfection with progressively elevated jaundice, coagulation dysfunction, and ascites and were diagnosed with ACLF. Eventually, they all died of multiorgan failure. Those with liver injury but no coagulation dysfunction generally went on to recover. These findings indicate that liver injury in patients with SARS-CoV-2 and chronic HBV coinfection was associated with disease severity and worse prognosis. Liver function should be evaluated more frequently in these special individuals, especially within a week after admission. Once liver injury occurs, it should be treated in timely manner to prevent poor prognosis, particularly for those with coagulation dysfunction.

Drug-induced liver injury has received more attention in recent years. Intravenous methylprednisolone was reported to be associated with acute liver injury, whereas data on association between oral methylprednisolone and liver injury are insufficient.[@bib20] In the present study, more patients with liver injury received methylprednisolone. Among them, half of patients received intravenous administration. Besides methylprednisolone, other drugs such as antibiotics, arbidol, lopinavir/ritonavir, interferon, and ribavirin may also cause liver injury.[@bib21], [@bib22], [@bib23] Most of the patients enrolled in this study received these drugs. No differences were observed in the use of these drugs between patients with and without liver injury except for interferon atomization therapy, which was given more to patients with liver injury. However, in the present study, not all patients experienced liver injury after these treatments. Three patients experienced liver injury before methylprednisolone therapy, and 2 patients experienced liver injury before interferon atomization therapy. Therefore, the association between these drugs and liver injury could not be further analyzed.

Besides drug-induced liver injury, the potential multifactorial etiologies of the liver injury are as follows. First, SARS-CoV-2 may act directly on the liver. Liver biopsy specimens of the patients with COVID-19 showed moderate microvascular steatosis and mild lobular and portal activity.[@bib24] Both SARS-CoV-2 and SARS-CoV could bind to the angiotensin-converting enzyme 2 (ACE2) receptor to enter the target cell. A preliminary study suggested that ACE2 receptor expression is enriched in cholangiocytes (not peer-reviewed).[@bib25] A latest ex vivo study found that human liver ductal organoids, which preserved the human-specific ACE2+ population of cholangiocytes, were permissive to SARS-CoV-2 infection and support robust replication. Notably, the barrier and bile acid transporting functions of cholangiocytes were impaired after virus infection (not peer-reviewed).[@bib26] These may explain the γ-GT elevation and consequent liver damage. Second, HBsAg-positive and hepatitis B core antibody--positive patients treated with corticosteroids have a risk of HBV reactivation (HBVr), and the anticipated incidence of HBVr ranged from \<1% to \>10% and is related to the dosage and course of corticosteroids treatment. The American Gastroenterological Association recommends antiviral prophylaxis for patients at high and moderate risk for HBVr undergoing immunosuppressive drug therapy but opposes routine antiviral prophylaxis for patients at low risk for HBVr.[@bib27] In our study, 30 patients received methylprednisolone therapy for a short time (less than 10 days). They all had a low risk of HBVr, so most of them did not receive anti-HBV therapy, with only 4 patients taking nucleotide/nucleoside analogue. Because of rapid deterioration of the disease, none of the 4 patients with ACLF were given anti-HBV treatment with consent of the patients or their families. The liver injury of these patients may be caused by HBVr or hepatitis flare. This indicates the clinical status of chronic HBV infection should be fully evaluated in the setting of corticosteroids, and nucleotide/nucleoside analogue therapy should be taken into account to reduce the risk of HBVr or hepatitis flare. Third, ischemic hypoxic liver injury caused by inflammation may also play a role. All these need to be further studied.

There were some limitations in our study. First, the present study was a retrospective, single-center study with relatively small sample size. Second, individuals with chronic HBV infection can transition through different clinical phases. In our study, almost all patients (97.14%) tested negative for HBeAg. Most of the patients (79.05%) had normal ALT levels at admission, and the other patients had elevated levels of ALT. Therefore, we can infer that most patients were inactive chronic hepatitis B or chronic hepatitis B.[@bib10] Because of lack of baseline levels of ALT and HBV DNA, patients could not be grouped according to the chronic HBV infection phases. Third, only a small proportion of patients (12.38%) received nucleotide/nucleoside analogue therapy; the impact of nucleotide/nucleoside analogue therapy on liver injury cannot be fully analyzed. Thus, the clinical features of patients with various clinical phases of chronic HBV infection after coinfection with SARS-CoV-2 and the mechanism of causing liver injury need to be further investigated.

In conclusion, we described the characteristics of liver function in patients with SARS-CoV-2 and chronic HBV coinfection. Patients with liver injury were more likely to progress to severe illness and had poor prognosis including higher rates of complications and death. During the treatment of COVID-19 in chronic HBV-infected patients, liver function should be taken seriously and evaluated frequently.
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